AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$ARTV

Aslan Fred sold $256K of ARTV

Aslan Fred (Chief Executive Officer) sold 23,429 shares of Artiva Biotherapeutics, Inc. (ARTV) at $10.92 ($0.26M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Aslan Fred
Published Sep 9, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The insider sale is modest and pre‑arranged, so market impact is expected to be minimal.

02

Market read

A routine insider sale with limited material effect on the stock.

03

What to watch

The sale was executed via a 10b5‑1 plan, indicating it was pre‑scheduled and not based on new information.

Relevance 3/10Novelty 4/10Timing: reported after market close on 2026-09-08

Background

Form 4 filings disclose insider transactions; they are primary sources for insider trading activity.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

CEO Aslan Fred sold 23,429 shares for $255,746, reducing his stake to 1,449,765 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale amount is small relative to market cap and typical insider trading volumes.

Market effects

Sector

None; the transaction is company‑specific and does not affect the biotech sector.

Regional

None; limited to Artiva investors.

Global

None

Counterpoint

What could challenge this read

If the CEO is reducing his position, it could signal concerns about near‑term prospects.

Key entities

  • Company
    Artiva Biotherapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker ARTV.

  • Person
    Aslan Fred

    Chief Executive Officer of Artiva Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARTV insider trading history →

Related articles

OCT 27
$ARTVLow

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent

SEC EDGAR 8-K2 min
OCT 27
$ARTVHighAI 8/10

Why is Artiva Biotherapeutics stock collapsing today?

Artiva Biotherapeutics' stock fell 30% after halting AlloNK (AB-101) development due to safety events and poor clinical data. The company plans to cut 94% of its workforce and explore strategic alternatives, including liquidation. CEO and COO sold shares before the announcement. Artiva had $319.1M in cash as of September 30. The stock traded at $4.31, far below its 52-week high of $14.53.

investing.com2 min